First Approved Treatment for Dry Age-Related Macular Degeneration Using Photobiomodulation

JANIS T. EELLS, PhD
Professor, Biomedical Sciences,
College of Health Sciences
Adjunct Professor, Epidemiology;
Epidemiology Track Lead
Joseph J. Zilber School of Public Health,
University of Wisconsin-Milwaukee

Adjunct Professor,
Department of Ophthalmology,
Medical College of Wisconsin,
Milwaukee, Wisconsin

MARION MUNK, MD, PhD, FEBO, FMH
Attending, Managing Director,
Bern Photographic Reading Center
Inselspital, University Hospital Bern;
Freiburgstrasse 4, 3010 Bern

Adjunct Faculty, Department
of Ophthalmology,
Northwestern University,
Feinberg School of Medicine

Chief Medical Officer,
Isarna Therapeutics

CLARK TEDFORD, PhD
President and CEO
LumiThera, Inc

The mechanism of photobiomodulation (PBM) at the cellular level has been ascribed to the activation of mitochondrial respiratory chain components resulting in stabilization of metabolic function and initiation of a signaling cascade, which promotes cellular proliferation and cytoprotection.

The learning objectives of this webinar are:

Understand the PBM mechanism of action
Review clinical data to support the efficacy and safety of PBM and the impact on anatomical and functional endpoints
Understand the importance of the use of multiple wavelengths in the development of the Valeda Light Delivery System

Webinar

First Approved Treatment for Dry Age-Related
Macular Degeneration Using Photobiomodulation

Wednesday, June 24, 2020 | 19:00 CET | 18:00 BST | 1:00 PM ET

Registration